CTRI/2023/08/057043尚未招募3 期
A prospective, single-arm, open-label, multi-centre study to evaluate the clinical efficacy and safety of CoviFight™ in reducing viral load in non-hospitalised COVID-19 patients. - COVIFIGHT-1
Meril Diagnostics Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patient =18 years of age.
- •2. Patient or their legal representative are willing to provide consent to participate in the study.
- •3. Patients with positive SARS-CoV-2 infection by antigen and qRT-PCR test (confirmed within 48 hours of randomization).
- •4. Patients presenting with mild SARS CoV-2 symptoms which may include but not limited to fever, cough, sore throat, fatigue, headache, muscle pain, diarrhea, nausea and vomiting, abdominal pain, lack of taste or smell, shortness of breath (within 48 hours of symptom onset) or no symptoms.
排除标准
- •1. Any clinical contraindications as judged by the Investigator.
- •2. Patient with concomitant respiratory therapy (oxygen or ventilator support).
- •3. Patient with prior SARS CoV-2 infection ( >48 hours from the time of screening).
- •4. Patients with severe or critical SARS CoV-2 severity symptoms and/or requiring hospitalization at the time of enrolment.
- •5. Lactating or pregnant women.
- •6. Patients on anti-platelet therapy.
- •7. Patients with pre-existing left ventricular dysfunction based on Investigator’s discretion.
- •8. Patients on nitric oxide donor compound therapy (sodium nitroprusside and nitroglycerin or prilocaine)
- •9. Patients with recent nasal surgeries or abnormalities in the nasal structure that might interfere with drug administration.
- •10. Patients with history of pollen allergy.
- •11. Patients on vasodilator therapy.
- •12. Patients with respiratory disorders like asthma, Chronic obstructive pulmonary disease (COPD) etc or history of pneumonia within 3 months of screening.
- •13. Patients with Stage-II Acute Kidney Injury
- •14. Patients vaccinated for COVID-19
- •15. Known allergy/hypersensitivity to Nitric Oxide
- •16. Not participating in any investigational drug or device study until completion of this study.
- •17. Patient on any intranasal medication or received any within last 7 days prior to screening
- •18. Patient on any anti-viral medication or received any within last 7 days prior to screening
研究者
相似试验
已完成
4 期
A prospective, single-arm, open-label, multi-centric to determine the safety and effectiveness of Anafortan â??N. Fixed-dose combination of Camylofin Dihydrochloride 50mg and Nimesulide 100mg in patients with acute colicky abdominal pain in IndiaCTRI/2018/10/016051Abbott Healthcare Pvt Ltd295
进行中（未招募）
4 期
A study to evaluate the efficacy and safety of Fixed Dose Combination of Glycopyrronium, Formoterol Fumarate, Budesonide in patients with chronic obstructive pulmonary disease.CTRI/2023/10/058791upin Limited
招募中
4 期
Study of MIRUSâ?¢ Disposable Hemorrhoids Stapler used in surgery during the treatment of prolapsed Hemorrhoids (Piles) to evaluate safety and efficacy of the device in post marketing period.CTRI/2017/05/008476Meril Endo Surgery Pvt Ltd80
撤回
不适用
A prospective, single-arm, open-label, multicenter clinical investigation to assess the safety and performance of SILKline breast implants in healthy female subjectsNL-OMON48726Polytech Health&Aesthetics GmbH30
已完成
4 期
A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic resonance imagingPulmonary Arterial HypertensionElevated blood pressure in blood vessels in the lungs.10037454NL-OMON45109Actelion Pharmaceuticals15